Freenome (FRNM) Q4 2025 earnings summary

Executive summary

• Blank check company focused on healthcare/life sciences, incorporated in March 2024, with no operating revenues to date and efforts limited to organizational activities and identifying a business combination target.

• Entered into a Business Combination Agreement with Freenome Holdings, Inc. in December 2025, expected to close in the first half of 2026, subject to shareholder and regulatory approvals.

• The transaction includes a domestication to Delaware, PIPE financing of $240 million, and a merger valuing Freenome at $725 million.

Financial highlights

• As of December 31, 2025, $91.9 million held in the trust account, with $5.6 million of investment income.

• Net income for 2025 was $837,468, driven by $3.8 million in interest income, offset by $3.0 million in operating costs.

• Working capital deficit of $1.35 million as of year-end 2025; cash outside the trust account was $865,031.

• No operating revenues; all income is from interest on trust account investments.

Outlook and guidance

• The company must complete a business combination by June 13, 2026, or liquidate and return funds to shareholders.

• Management plans to complete the Freenome transaction before the deadline but notes substantial doubt about the ability to continue as a going concern if not completed.

• No assurance of successful completion of the business combination; no guidance on future operating results.